NCT07222241 Comparing Numbing Techniques in Mohs Micrographic Surgery
| NCT ID | NCT07222241 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Skin Cancer Face |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2026-01-27 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2026-01-27 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study seeks to determine whether adjunct regional nerve blocks reduce pain and anxiety in adult patients undergoing Mohs micrographic surgery for face and scalp skin cancers. Participants will be randomized to one of two arms: (1) placebo regional nerve block with sterile normal saline or (2) adjunct regional nerve block with lidocaine. All patients receive local infiltration with lidocaine for complete anesthesia.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years. * Scheduled to undergo MMS. * Lesions on the face or scalp, defined as the region superior to the mandibular margin anteriorly, superior to the external occipital protuberance posteriorly, and superior to the mastoid processes laterally. * Tumor diameter plus anticipated stage 1 MMS margin ≥2 cm in diameter OR any tumor on the ear, lip, nose, or eyelid. * Ability to complete patient reported outcome measures in English. Exclusion Criteria: * Known allergy or contraindication to lidocaine or epinephrine. * Chronic opioid use or pre existing pain disorders that may interfere with pain reporting. * Presence of scar tissue at the anatomic site of local infiltration or nerve block that may alter anesthetic penetration. * Concurrent multi site Mohs procedure. * Signs of skin and soft tissue infection at the anatomic site of local infiltration or nerve block. * Inability to understand or complete pain and satisfaction assessments. * Pregnant or breastfeeding. * Use of sedatives or anxiolytics prior to the procedure.
Contact & Investigator
Kaiyu Ma Clinical research regulatory specialist, PhD
✉ makaiyu@pennmedicine.upenn.edu📞 215-662-2123
Christopher Miller, MD
PRINCIPAL INVESTIGATOR
Univerisity of Pennsylvania
Frequently Asked Questions
Who can join the NCT07222241 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Skin Cancer Face. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07222241 currently recruiting?
Yes, NCT07222241 is actively recruiting participants. Contact the research team at makaiyu@pennmedicine.upenn.edu for enrollment information.
Where is the NCT07222241 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07222241 clinical trial?
NCT07222241 is sponsored by Abramson Cancer Center at Penn Medicine. The principal investigator is Christopher Miller, MD at Univerisity of Pennsylvania. The trial plans to enroll 150 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.